Option Care Health, Inc.
OPCHOption Care Health, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (21 weeks in) while the P/E sits at the 9th percentile of its own 5-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, and 138% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Option Care Health, Inc. trades at $24.5, in a downtrend and 21 weeks into that stage. That is −9.3% against its own 200-day average. It sits at 30% of a 52-week range of $20 to $36. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 8 straight weeks.
Today the stock is in a downtrend — week 21 of stage 4. At $24.5 it trades −9.3% versus its 200-day average and sits at 30% of its 52-week range ($20–$36).
Against the market, two honest reads. Cumulative: over the last 7.1 years the stock moved +110% while the S&P 500 moved +159% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Option Care Health, Inc. trades at 18.5× P/E, near the bottom of its own range — cheaper only 9% of the time. Its long-run median P/E is 25.3×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 18.5× is near the bottom of its own range — cheaper only 9% of the time, against a long-run median of 25.3× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +3.3% against a −13.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the −11.1%/yr price move, ~−0.5%/yr came from earnings growth and ~−10.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Option Care Health, Inc. reads as improving on its fundamental arc. Improving — EPS growth bottomed 4 quarters ago at −17.0% and has held its recovery at +4.0%, ROCE holding at 12.2%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +13.0% | +12.8% | — | — |
| Profit | +0.0% | +11.9% | — | — |
| EPS | +3.3% | +15.2% | — | — |
| Stock price | −13.6% | −11.1% | −1.0% | — |
4-Factor Sector Score
43.5/100 — rank 21 of 30 in Medical Care Facilities · 58% evidence confidence
Option Care Health, Inc. scores 43.5 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 21. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 17.3 + 11.3 + 9.9 + 5 = 43.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Option Care Health, Inc. reported $1.4 B of revenue in the Mar 26 quarter, +1.5% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 13.2% a year. The last full year, FY25, came in at $5.7 B. The last four reported quarters add to $5.7 B.
FY25 revenue came in at $5.7 B (+13.0% on the year), capping 4 years at 13.2% compound. The latest quarter (Mar 26) printed $1.4 B, +1.5% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +9.6% growth against the decade's 13.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +9.4% over the last 4 quarters against +13.2%/yr over the last 8 — rolling over; TTM profit +0.0% vs −11.8%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Option Care Health, Inc.'s operating margin is 5.2% in the Mar 26 quarter, −0.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.5% to 7.2%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 5.2%, −0.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.5%–7.2%.
🚨 Why the margin moved: operating margin went −0.8 pp year on year while gross margin went −0.2 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Option Care Health, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.2 B. The 4-year compound rate is 10.7%. That is 3.7% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Mar 26 profit was $0.1 B, +0.0% year on year. On the full year, FY25 printed $0.2 B (+0.0%), and the 4-year compound rate is 10.7%.
🚨 Why profit moved: revenue contributed +1.5% and the margin −0.8 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +0.0% vs revenue +9.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 138% of Option Care Health, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.3 B of operating cash against $0.2 B of profit. After $0.0 B of capital spending, $0.2 B was left as free cash.
FY25: operating cash of $0.3 B against reported profit of $0.2 B, leaving free cash of $0.2 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 138% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Option Care Health, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Option Care Health, Inc. earns a ROE of 16% in FY25. That is up from a trough of 11% in FY22. Return on invested capital clears the cost of that capital by +3.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 3.7% net margin on 1.63× asset turns.
FY25 ROE is 16%, recovered from a FY22 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 3.7% net margin × 1.63× asset turns × 2.60× balance-sheet leverage ≈ 15.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.3% − 6.5% = a +3.8 pp spread. The 6.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend
Option Care Health, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Option Care Health, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Option Care Health, Inc. carries total debt of $1.3 B against shareholder equity of $1.3 B as of Jun 26, a debt-to-equity of 1.01. On the annual view that ratio went from 0.98 in FY21 to 0.95 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $1.3 B against shareholder equity of $1.3 B — a debt-to-equity of 1.01. On the annual view, debt-to-equity went from 0.98 (FY21) to 0.95 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
8.6% of Option Care Health, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 6.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 8.6% of the float is sold short, and at typical trading volumes it would take about 6.0 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Option Care Health, Inc.: the Z-score reads 3.84. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.84 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.84.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Tenet Healthcare CorporationTHC | 65.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 24.1/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 16.4/25 ROCE 5.8% · OPM 23.2% 76% evidence | 11.0/20 P/E 7.2× · PEG — 15% evidence | 13.7/20 RS sector -3.7% · RS bench 18.8% · 1Y 39.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 24.1 + 16.4 + 11 + 13.7 = 65.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Concentra Group Holdings Parent, Inc.CON | 62.0/100Mixed-positive evidence71% evidence | LEADER | 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence | 14.7/25 ROCE 3.8% · OPM 16.8% 76% evidence | 10.1/20 P/E 15.4× · PEG — 15% evidence | 17.4/20 RS sector 13.5% · RS bench 38% · 1Y 76%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.7 + 10.1 + 17.4 = 62 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Encompass Health CorporationEHC | 61.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 20.8/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence | 15.8/25 ROCE 4.9% · OPM 19% 76% evidence | 14.0/20 P/E 16.1× · PEG 0.68 65% evidence | 10.9/20 RS sector -15.3% · RS bench 5.4% · 1Y -0.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 15.8 + 14 + 10.9 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Addus HomeCare CorporationADUS | 56.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence | 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence | 13.4/20 P/E 17.3× · PEG 0.78 65% evidence | 10.0/20 RS sector -17.2% · RS bench 3% · 1Y 5.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.3 + 13.4 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Nutex Health Inc.NUTX | 55.9/100Mixed-positive evidence75% evidence | LEADER | 17.5/35 Revenue 40.8% · PAT 31.3% · OPM change -0.6 pp 83% evidence | 15.9/25 ROCE 12.1% · OPM 37.5% 76% evidence | 6.8/20 P/E 6.9× · PEG 2.9 65% evidence | 15.7/20 RS sector 20.7% · RS bench 47.8% · 1Y 126.1%11 of 12 weeks ahead 70% evidence |
| Exact sum: 17.5 + 15.9 + 6.8 + 15.7 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6LifeStance Health Group, Inc.LFST | 55.4/100Mixed-positive evidence64% evidence | LEADER | 22.4/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence | 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence | 8.5/20 P/E 106.2× · PEG — 15% evidence | 18.7/20 RS sector 25.5% · RS bench 51.5% · 1Y 144.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.4 + 5.8 + 8.5 + 18.7 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aveanna Healthcare Holdings Inc.AVAH | 54.4/100Thin evidence · provisional58% evidence | LEADER | 11.7/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence | 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence | 11.4/20 P/E 5.4× · PEG — 15% evidence | 19.5/20 RS sector 24.4% · RS bench 53.1% · 1Y 76%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 11.8 + 11.4 + 19.5 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8PACS Group, Inc.PACS | 53.7/100Thin evidence · provisional56% evidence | LEADER | 22.2/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence | 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence | 9.1/20 P/E 31.5× · PEG — 15% evidence | 9.1/20 RS sector -2.3% · RS bench 18.1% · 1Y 256.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 13.3 + 9.1 + 9.1 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Chemed CorporationCHE | 53.4/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.2/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 15.6/25 ROCE 6.6% · OPM 12.9% 76% evidence | 9.3/20 P/E 23.4× · PEG — 15% evidence | 10.3/20 RS sector -13.8% · RS bench 6.4% · 1Y 12.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 15.6 + 9.3 + 10.3 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Fresenius Medical Care AGFMS | 52.9/100Mixed-positive evidence81% evidence | ASLEEP | 21.9/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence | 11.3/25 ROCE 2.1% · OPM 11.7% 76% evidence | 15.7/20 P/E 11.9× · PEG 0.22 65% evidence | 4.0/20 RS sector -27% · RS bench -9% · 1Y -9.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 11.3 + 15.7 + 4 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Guardian Pharmacy Services, Inc.GRDN | 51.0/100Mixed-positive evidence64% evidence | TURNING | 17.6/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence | 12.3/25 ROCE 7.8% · OPM 5.3% 76% evidence | 8.7/20 P/E 45.4× · PEG — 15% evidence | 12.4/20 RS sector 3% · RS bench 25.9% · 1Y 82.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 12.3 + 8.7 + 12.4 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12HCA Healthcare, Inc.HCA | 50.9/100Mixed-positive evidence85% evidence | BREAKING OUT | 14.6/35 Revenue 7.3% · PAT 14.1% · OPM change -0.7 pp 95% evidence | 15.6/25 ROCE 6.9% · OPM 15.2% 76% evidence | 15.1/20 P/E 13.1× · PEG 0.51 65% evidence | 5.6/20 RS sector -28.6% · RS bench -10.7% · 1Y 7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 15.6 + 15.1 + 5.6 = 50.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Healthcare Services Group, Inc.HCSG | 50.8/100Thin evidence · provisional52% evidence | FADING | 23.0/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 10.7/25 ROCE 3.6% · OPM 7.3% 76% evidence | 10.3/20 P/E 14.3× · PEG — 15% evidence | 6.8/20 RS sector -17.5% · RS bench 1.4% · 1Y 38.3%6 of 12 weeks ahead 70% evidence |
| Exact sum: 23 + 10.7 + 10.3 + 6.8 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14National HealthCare CorporationNHC | 48.7/100Mixed-negative evidence81% evidence | LEADER | 16.9/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence | 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence | 9.8/20 P/E 20.3× · PEG 1.48 65% evidence | 11.8/20 RS sector 2.7% · RS bench 24.7% · 1Y 92.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 10.2 + 9.8 + 11.8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Universal Health Services, Inc.UHS | 48.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.0/25 ROCE 4.1% · OPM 11.2% 76% evidence | 11.3/20 P/E 6.1× · PEG — 15% evidence | 6.1/20 RS sector -29.4% · RS bench -11.2% · 1Y -3.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 14 + 11.3 + 6.1 = 48.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16agilon health, inc.AGL | 47.6/100Mixed-negative evidence61% evidence | FADING | 18.8/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence | 4.8/25 ROCE 1% · OPM 0.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.0/20 RS sector 54% · RS bench 76.9% · 1Y 209.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 4.8 + 10 + 14 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17The Pennant Group, Inc.PNTG | 46.7/100Mixed-negative evidence75% evidence | LEADER | 20.3/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence | 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence | 4.0/20 P/E 35.9× · PEG 3.03 65% evidence | 13.2/20 RS sector 1.7% · RS bench 24.3% · 1Y 76.1%11 of 12 weeks ahead 70% evidence |
| Exact sum: 20.3 + 9.2 + 4 + 13.2 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18The Ensign Group, Inc.ENSG | 45.9/100Thin evidence · provisional58% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 12.2/25 ROCE 2.7% · OPM 9% 76% evidence | 9.2/20 P/E 25.1× · PEG — 15% evidence | 6.4/20 RS sector -26.6% · RS bench -8.6% · 1Y 8.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 12.2 + 9.2 + 6.4 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19DaVita Inc.DVA | 45.5/100Mixed-negative evidence81% evidence | ASLEEP | 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence | 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence | 8.2/20 P/E 14.3× · PEG 2.08 65% evidence | 7.5/20 RS sector -5.3% · RS bench 14.9% · 1Y 48.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 13.7 + 8.2 + 7.5 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Pediatrix Medical Group, Inc.MD | 45.3/100Mixed-negative evidence74% evidence | LEADER | 17.7/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence | 10.1/25 ROCE 2.5% · OPM 8.7% 76% evidence | 10.0/20 P/E 10.4× · PEG 1.7 65% evidence | 7.5/20 RS sector -10.7% · RS bench 9.7% · 1Y 60.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 10.1 + 10 + 7.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Option Care Health, Inc.this pageOPCH | 43.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence | 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence | 9.9/20 P/E 15.8× · PEG — 15% evidence | 5.0/20 RS sector -33.3% · RS bench -16.1% · 1Y -13.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 11.3 + 9.9 + 5 = 43.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Acadia Healthcare Company, Inc.ACHC | 42.8/100Thin evidence · provisional58% evidence | LEADER | 15.1/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence | 9.5/20 P/E 21.2× · PEG — 15% evidence | 10.7/20 RS sector -5.6% · RS bench 14.9% · 1Y 27.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 7.5 + 9.5 + 10.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Select Medical Holdings CorporationSEM | 40.3/100Mixed-negative evidence75% evidence | 11.0/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence | 9.8/25 ROCE 2% · OPM 6.9% 76% evidence | 12.9/20 P/E 15.4× · PEG 0.93 65% evidence | 6.6/20 RS sector -23% · RS bench 1.5% · 1Y 9%0 of 1 week ahead to 2026-07-02 70% evidence | |
| Exact sum: 11 + 9.8 + 12.9 + 6.6 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Ardent Health, Inc.ARDT | 40.2/100Mixed-negative evidence65% evidence | BREAKING OUT | 14.5/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence | 8.8/25 ROCE 1.9% · OPM 5.1% 76% evidence | 10.9/20 P/E 9× · PEG — 15% evidence | 6.0/20 RS sector -21.3% · RS bench -1.8% · 1Y -16.4%8 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 8.8 + 10.9 + 6 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Astrana Health, Inc.ASTH | 39.7/100Mixed-negative evidence81% evidence | ASLEEP | 14.5/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence | 7.4/25 ROCE 2.2% · OPM 3% 76% evidence | 10.5/20 P/E 40.2× · PEG 1.17 65% evidence | 7.3/20 RS sector -6.8% · RS bench 13.6% · 1Y 35.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 7.4 + 10.5 + 7.3 = 39.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26InnovAge Holding Corp.INNV | 38.1/100Thin evidence · provisional58% evidence | LEADER | 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence | 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence | 8.6/20 P/E 103.8× · PEG — 15% evidence | 15.1/20 RS sector 8.9% · RS bench 31.1% · 1Y 134.3%12 of 12 weeks ahead 70% evidence |
| Exact sum: 10.8 + 3.6 + 8.6 + 15.1 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Sonida Senior Living, Inc.SNDA | 36.0/100Mixed-negative evidence64% evidence | BREAKING OUT | 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence | 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence | 11.5/20 P/E 1.9× · PEG — 15% evidence | 7.7/20 RS sector -12.4% · RS bench 7.5% · 1Y 46.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 3.8 + 11.5 + 7.7 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Surgery Partners, Inc.SGRY | 35.1/100Mixed-negative evidence61% evidence | ASLEEP | 14.2/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence | 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -33.9% · RS bench -17% · 1Y -35.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 7.2 + 10 + 3.7 = 35.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Brookdale Senior Living Inc.BKD | 33.5/100Adverse evidence61% evidence | ASLEEP | 17.3/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence | 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.2/20 RS sector -29.3% · RS bench -13.2% · 1Y 47.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 5 + 10 + 1.2 = 33.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30COMPASS Pathways plcCMPS | 48.2/100Thin evidence · provisional47% evidence | LEADER | 20.0/35 Revenue — · PAT — · OPM change — 33% evidence | 5.0/25 ROCE -12.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.2/20 RS sector 23.6% · RS bench 48.2% · 1Y 181.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 5 + 10 + 13.2 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Option Care Health, Inc.'s stock price today?
Option Care Health, Inc. trades at $24.5, −13.6% over the past year. The company is valued at $4.0 B. The stock sits at 30% of its 52-week range of $20–$36, −9.3% versus its 200-day average. On the tape, the price is in a downtrend, 21 weeks in. — as of 17 September 2026.
What were Option Care Health, Inc.'s latest quarterly results?
Option Care Health, Inc. reported revenue of $1.4 B and net profit of $0.1 B for the Mar 26 quarter. Revenue rose 1.5% and profit rose 0.0% year on year. Earnings per share were $0.29. The operating margin was 5.2%, 0.8 pp lower than a year earlier. — as of 17 September 2026.
What is Option Care Health, Inc.'s revenue?
Option Care Health, Inc. reported revenue of $1.4 B in the Mar 26 quarter, +1.5% year on year. For the full FY25 fiscal year, revenue was $5.7 B (+13.0%). Over the last 4 years revenue compounded at 13.2% a year. — as of 17 September 2026.
What is Option Care Health, Inc.'s profit?
Option Care Health, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.2 B. The operating margin ran 5.2% in the latest quarter. — as of 17 September 2026.
What is Option Care Health, Inc.'s market cap?
Option Care Health, Inc.'s market capitalisation is $4.0 B at a stock price of $24.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Option Care Health, Inc.'s P/E ratio?
Option Care Health, Inc. trades at a P/E of 18.5×, at the 9th percentile of its own 5-year range, against a long-run median of 25.3×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Option Care Health, Inc. pay a dividend?
No — Option Care Health, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Option Care Health, Inc. overvalued?
On its own history, Option Care Health, Inc. looks cheap: its P/E of 18.5× has been cheaper only 9% of the time in 5 years (long-run median 25.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Option Care Health, Inc. growing?
The picture is mixed for Option Care Health, Inc.: latest-quarter revenue +1.5% year on year, profit +0.0%, and the margin −0.8 pp at 5.2%. The 4-year compound rates are 13.2% (revenue) and 10.7% (profit). The earnings engine currently reads: mixed — as of 17 September 2026.
How is Option Care Health, Inc. performing?
Option Care Health, Inc. is in a downtrend, 21 weeks in. Its latest quarter's revenue rose 1.5% and profit rose 0.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Option Care Health, Inc. in?
Improving — EPS growth bottomed 4 quarters ago at −17.0% and has held its recovery at +4.0%, ROCE holding at 12.2%. The read comes from the last 12 quarters of growth (revenue growth +9.4% latest, profit growth +0.0% latest, eps growth +4.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Option Care Health, Inc. in an uptrend?
No — the price is in a downtrend (week 21 of stage 4), trading −9.3% versus its 200-day average and at 30% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Option Care Health, Inc. beating the market?
On recent form, yes — Option Care Health, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7.1 years the stock moved +110% against the S&P 500's +159% — behind the index over the full window. — as of 17 September 2026.
Will Option Care Health, Inc.'s stock price go up?
This page publishes no price forecast for Option Care Health, Inc. What it measures instead: the stock price is $24.5, the price is in a downtrend 21 weeks in. Its P/E of 18.5× sits at the 9th percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against Option Care Health, Inc.?
Somewhat — short interest is 8.6% of Option Care Health, Inc.'s tradable float, about 6.0 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Option Care Health, Inc. have too much debt?
It carries real leverage — Option Care Health, Inc.'s debt-to-equity is 1.01. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Option Care Health, Inc.'s capex?
Option Care Health, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is Option Care Health, Inc.'s cash flow?
Option Care Health, Inc. generated $0.3 B of operating cash flow in FY25 and $0.2 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Option Care Health, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 138% of Option Care Health, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.3 B against reported profit of $0.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Option Care Health, Inc.?
On the balance sheet, the Z-score reads 3.84 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Option Care Health, Inc. in its business cycle?
Option Care Health, Inc.'s FY25 operating margin was 6.0%, against a 5-year band of 5.5%–7.2%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 5.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Option Care Health, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Option Care Health, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Option Care Health, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!